Medical Cyclotron Market Analysis & Forecast: 2026-2033
The Medical Cyclotron Market is estimated to be valued at USD 235 Mn in 2026 and is expected to reach USD 357 Mn by 2033, growing at a compound annual growth rate (CAGR) of 6.1% from 2026 to 2033.
The medical cyclotron market is advancing significantly with the rising applications in nuclear medicine, oncology, and personalized diagnostics. Moreover, expanding radiopharmaceutical research and tightening regulatory standards for isotope production are expected to drive market growth over the forecast period. The medical cyclotrons are specialized particle accelerators that use electromagnetic fields to propel charged particles, primarily protons, at high speeds. This technology is a cornerstone of modern molecular imaging, facilitating the on-site production of short-lived radioisotopes.
|
Current Event |
Description and the Impact |
|
Technological Innovations and Advancements |
|
|
Public Health and Disease Burden Trends |
|
|
Economic and Healthcare Infrastructure Trends |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
In terms of product type, the fixed energy cyclotron segment contributes the highest share of 39.90% in 2026 of the market. The growth is owing to its specialized efficiency in producing standard positron emitting isotopes like Fluorine-18. Unlike variable energy models, fixed energy systems offer simplified operational protocols and lower maintenance requirements along with a more compact footprint. These characteristics make them ideal for the burgeoning network of regional radiopharmacies. These cyclotrons act as the primary workhorses of the industry by providing the yield stability necessary for the mass production of FDG. The operational stability and comparatively lower capital outlay associated with fixed energy systems make them the dominant choice among commercial suppliers and large-scale medical facilities focused on strengthening diagnostic isotope supply chain resilience.
In terms of application, the diagnostic and treatment segment contributes the highest share of 77.20% in 2026 of the market. The segment is growing as nuclear medicine becomes central to oncology and cardiology. The growth is owing to the rising prevalence of chronic diseases and the subsequent need for high-resolution molecular imaging. The medical cyclotrons are indispensable for the creation of radiotracers used in PET and SPECT scans. They allow for earlier and more accurate disease detection than traditional imaging methods. In addition, the treatment aspect is gaining momentum via theranostics, which is a dual approach where cyclotrons produce both diagnostic and therapeutic isotopes. This shift toward personalized medicine ensures that the diagnostic and treatment segment remains the primary revenue engine for the medical cyclotron market.
For instance, in October 2024, The African Medical Centre of Excellence (AMCE) has begun constructing a modern medical facility equipped with state-of-the-art imaging technology vital for diagnosing and treating diseases like cancer, cardiovascular issues, and neurological disorders. The center's facilities will include a Cyclotron, which will improve both diagnostic and therapeutic capabilities.
In terms of end user, the hospitals segment contributes the highest share of 34.10% in 2026 of the market. The growth is owing to a strategic shift toward decentralized radiopharmaceutical production, where large hospital networks install in-house cyclotrons in order to ensure a steady supply of short-lived isotopes. The hospitals can offer more flexible patient scheduling and reduce procedural expenses by bypassing the logistical challenges of transporting isotopes with rapid decay rates. In addition, the integration of cyclotron facilities within comprehensive cancer centers allows for a seamless transition between diagnosis and specialized treatments like proton therapy. The increasing public and private investment in cutting-edge hospital infrastructure ensures that this segment is at the forefront of the market growth.
For instance, in November 2025, Precious Medical Group has announced the opening of the Tunku Laksamana Johor Cancer Centre and Hospital. It will also feature a nuclear medicine facility that includes Malaysia's first cyclotron outside the Klang Valley, allowing for the on-site production of medical radioisotopes used in cancer imaging and therapy.
To learn more about this report, Download Free Sample
North America has emerged as the leader in the global market and accounts for a higher share of 37.50% in 2026. The growth is due to the increasing prevalence of chronic diseases, particularly cancer, which has created a demand for more precise diagnostic imaging and targeted therapies. The region currently possesses the largest market share. The increase is owing to by its advanced healthcare infrastructure and a high concentration of specialized medical facilities. There are over 250 installed cyclotrons in North America.
The market is evolving due to the emergence of theranostics, which combines diagnostic imaging with targeted therapeutic isotopes like Lutetium-177 and Actinium-225. This advancement necessitates the use of higher-energy machines. The major global firms such as GE HealthCare, Siemens Healthineers, and IBA Radiopharma Solutions lead the competitive landscape. They are placing a greater emphasis on integrating AI and automation into their systems to enhance isotope yields and minimize operational downtime.
For instance, in May 2023, Advanced Cyclotron Systems, Inc. (ACSI) has announced the initial sale of its new TR-ALPHA. This new cyclotron was designed, developed, and manufactured in Canada. This innovative technology provides healthcare and research organizations with an opportunity to save space and reduce costs.
The Asia Pacific region is the fastest growing region in the global Medical Cyclotron Market. The growth is owing to the rising prevalence of cancer and neurological disorders in the region. This rise has resulted in a higher demand for Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT) imaging. In addition, there is a notable shift toward on site isotope production. This is because hospitals are seeking to reduce their dependence on external supply chains and minimize logistical delays associated with short-lived isotopes.
China is operating more than 120 cyclotrons and has a national plan to double its isotope services by 2035. India is experiencing fast growth in the region owing to substantial investments in oncology infrastructure. The firms like IBA, GE HealthCare, and Siemens Healthineers are implementing AI-driven automation and IoT-enabled monitoring in their systems to improve isotope yields and reduce operational downtime.
For instance, in November 2025, Telix has announced that its TMS (Telix Manufacturing Solutions) facility in Yokohama, Japan, has officially opened. This facility marks the Company’s first cyclotron site in the Asia Pacific region.
The U.S. remains the most profitable market for Medical Cyclotron globally. The growth is owing to the high volume of diagnostic imaging procedures. The rising cancer incidences are creating an increased demand for cyclotron-produced tracers like Fluorine-18. The new technology is making hospitals choose smaller, self-shielded 10-12 MeV cyclotrons for producing isotopes on-site. This shift aims to ensure isotope sovereignty and lessen reliance on external supply chains. At the same time, the growing field of theranostics is fueling investment in higher-energy systems that can produce therapeutic isotopes like Actinium-225 and Lutetium-177. The competitive landscape is led by firm like GE HealthCare, Siemens Healthineers, and IBA Radiopharma Solutions. They are focusing on AI-driven automation to enhance isotope yields.
For instance, in January 2026, CyGen Alpha Systems LLC has unveiled its new radiopharmaceutical infrastructure platform. It aims to increase domestic capacity for cutting eddge nuclear medicine and precision oncology. The firm is currently assessing potential sites for its inaugural U.S. Medical Cyclotron facility.
China is the fastest growing market for Medical Cyclotron owing to the aggressive national mandate to decentralize and modernize nuclear medicine services. Under the Medium- and Long-term Development Plan for Medical Isotopes, the Chinese government aims to establish a nuclear medicine department in every county-level hospital, a goal that is projected to at least double the current scale of the industry by 2035. The market continues to expand fueled by a surge in domestic demand for Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT) imaging to address rising cancer and cardiovascular disease rates. High-energy medical cyclotrons (above 24 MeV) have become a strategic focus for China supported by massive investments in world-class research institutions and new large-scale cancer centres.
For instance, in December 2023, GE Healthcare China has introduced its first batch of cyclotrons at Chengdu Tianfu International Bio-Town, located in Chengdu, the capital of Sichuan province. This initiative marks a significant step for GE Healthcare China, a subsidiary of the US-based medical technology company GE Healthcare.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 235 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.1% | 2033 Value Projection: | USD 357 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
IBA Radiopharma Solutions, Advanced Cyclotron Systems, Best Cyclotron Systems, Inc., Best ABT Molecular Imaging, Inc., Siemens Healthineers, GE Healthcare, IONETIX Corporation, PMB-ALCEN, Sumitomo Heavy Industries, Ltd., and The Japan Steel Works, Ltd. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
The global medical cyclotron market is witnessing a considerable surge in demand owing to the critical need for a stabilized and localized supply of radioisotopes. The rising global prevalence of cancer and neurodegenerative diseases forces healthcare providers to expand their use of advanced diagnostic imaging techniques like Positron Emission Tomography. Many essential isotopes used in these procedures have extremely short half-lives and must be produced near the point of care to remain effective.
This logistical need has led to a move away from traditional nuclear reactors toward cyclotrons, which provide a more efficient and safer way to produce isotopes. In addition, the growth of theranostic, which combines diagnostic imaging with targeted treatment, is encouraging hospitals and pharmaceutical companies to invest in high-energy cyclotrons. These systems can produce new isotopes like Actinium 225, which are important for personalized medicine. As a result, increasing adoption of on-site production is expected to drive stable market expansion while safeguarding patient access. to key radiopharmaceuticals.
The Medical Cyclotron Market is a pivotal segment within nuclear medicine and advanced diagnostic imaging, driven by the essential role of cyclotrons in producing short‑lived isotopes—especially fluorine‑18—for PET imaging. Industry assessments consistently show a robust and sustained growth trajectory, reflecting expanding deployments and rising demand for on‑site radioisotope production.
Analysis of installed units worldwide indicates well over a thousand Medical Cyclotrons currently in operation, with a significant proportion being low‑energy systems optimized for producing common diagnostic isotopes. Diagnostic applications—particularly oncology, cardiology, and neurology PET scans—account for a dominant share of cyclotron usage, with diagnostic procedures representing the vast majority of market activity. Hospitals remain the largest end‑user segment, although diagnostic imaging centers and radiopharmaceutical producers are increasingly investing in cyclotron capacity to ensure reliable supply and support innovation.
Share
Share
About Author
Manisha Vibhute is a consultant with over 5 years of experience in market research and consulting. With a strong understanding of market dynamics, Manisha assists clients in developing effective market access strategies. She helps medical device companies navigate pricing, reimbursement, and regulatory pathways to ensure successful product launches.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
Schedule a meeting with report Author
